SCHEMBL2158176

SCHEMBL2158176

Cc1ccc(S(=O)(=O)Nc2csc(-c3ccccc3)c2)c(C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
MAPT P10636 5/20 0.52
HPGD P15428 3/20 0.52
POLB P06746 2/20 0.52
ALOX12 P18054 2/20 0.52
GFER P55789 2/20 0.52
KMT2A Q03164 4/20 0.51
HSD17B10 Q99714 2/20 0.50
LMNA P02545 4/20 0.48
PKM P14618 2/20 0.48
HTT P42858 2/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TP53 P04637 2/20 0.47
MEN1 O00255 3/20 0.46
MAP1LC3B Q9GZQ8 1/20 0.46
KDM4E B2RXH2 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158054 0.90 ALDH1A1 (0.52) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL2158433 0.88 RXFP1 (0.48) ALDH1A1MAPTPOLBKMT2APKM
SCHEMBL2157624 0.88 CNR1 (0.49) POLBKMT2AMEN1BRPF1
SCHEMBL2157816 0.88 CA1 (0.44) ALDH1A1MAPTHPGDPOLBALOX12
SCHEMBL2157872 0.85 ALPL (0.55) ALDH1A1HPGDKMT2ALMNAPKM
SCHEMBL2158856 0.84 SMN1; SMN2 (0.56) ALDH1A1MAPTPOLBGFERKMT2A
SCHEMBL2158669 0.83 MEN1 (0.53) KMT2APKMSMN1; SMN2MEN1TDP1
SCHEMBL2157622 0.82 ALDH1A1 (0.55) ALDH1A1MAPTHPGDKMT2ALMNA
SCHEMBL2158510 0.81 LMNA (0.45) ALDH1A1MAPTHPGDPOLBGFER
SCHEMBL12464422 0.80 ALDH1A1 (0.54) ALDH1A1MAPTKMT2ATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985769-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20060142347-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2006-06-29 US disclosed
US-6881741-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142347-A1 Compounds and methods for the treatment or prevention of Flavivirus infections HAVCR2, ZC3HAV1, MAVS ALDH1A1 684/4885MAPT 1458/4885HPGD 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.